EDGAR·FLOW

Cullinan Therapeutics, Inc. — Form 8-K

Filed November 9, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Cullinan's BCMAxCD3 T cell engager velinotamig (licensed from Genrix Bio) treated 12 patients across three dose cohorts as of September 8, 2026. Among 9 evaluable patients with ≥4 weeks follow-up, 8 of 9 achieved ≥4-point SLEDAI-2K reduction; 4 of 7 with baseline proteinuria >500 mg/24h achieved complete renal response (<500 mg/24h) within 24 weeks. Safety profile was favorable: zero dose-limiting toxicities, zero ICANS, no Grade 3+ CRS (only Grade 1–2 in 2 patients, resolved with standard management).
Why this rating

Early Phase 1b/2a data in high-unmet SLE nephritis on lead asset; strong efficacy signals (89% SLEDAI response, 57% complete renal response) and clean safety support pipeline value. For $442M market-cap stage-company, positive clinical validation of core mechanism is material but still early; de-risking ahead of Phase 2 expansion.

Tradability signal
NO TRADE

No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$11.32
+10 min · unknown
$10.96 ▼ 3.18%
+30 min · unknown
$11.31 ▼ 0.09%
+1 hr · unknown
$11.69 ▲ 3.22%
+4 hrs · unknown
$12.20 ▲ 7.77%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ CGEM · stock on Yahoo Finance ↗

See more from November 9, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.